transfusion prophylaxis. The underlying mechanisms of harm reported in randomized trials may be related to the role of platelets beyond hemostasis, including mediating inflammation. Research supports the implementation of a restrictive platelet transfusion policy. Research is needed to better understand the ...
In our practice, we do not recommend treatment initiation for asymptomatic patients with advanced, low-burden iNHL because of the lack of survival benefit, because 20–30% of patients will not meet treatment criteria for at least 10 years, and the median time to treatment in newly diagnosed pa...